Lamotrigine rechallenge in treatment-resistant bipolar disorder

Takayoshi Inaba, Rintaro Sogawa, Yoshito Mizoguchi, Hiroshi Tateishi, Yutaka Kunitake, Takahiro A. Kato, Akira Monji

Research output: Contribution to journalReview article

Abstract

Background: Although lamotrigine may be useful for treating patients with treatment-resistant bipolar disorder, some lamotrigine-associated adverse effects, including mild to moderate skin rash, may prevent the continuation of treatment. Methods: We investigated lamotrigine rechallenge for the treatment of bipolar disorder. The present study was based on retrospective chart review of outpatients with bipolar disorder (DSM-5 criteria) who visited the hospital’s psychiatric department between July 2011 and August 2017. The review revealed 12 patients with bipolar disorder who underwent lamotrigine rechallenge following lamotrigine discontinuation due to various adverse reactions, including skin rash. None of the patients showed Stevens-Johnson syndrome. All patients suffered from treatment-resistant bipolar disorder that was refractory to treatments other than lamotrigine. For each patient, the severity of the adverse reaction to lamotrigine was weighed against the potential for therapeutic benefit. Results: In 9 of 12 cases, a positive outcome of lamotrigine rechallenge was observed. In all cases with initial skin rash with very slow titration of lamotrigine, rechallenge was successful with no recurrence of the rash. In the 3 cases for which lamotrigine was unsuccessful, lamotrigine was discontinued owing to movement disorders, ie, oral dyskinesia and action tremor, and liver dysfunction, respectively. Conclusions: The present results suggest that lamotrigine rechallenge may be a viable option for treatment-resistant bipolar disorder.

Original languageEnglish
Article number17m02231
JournalPrimary Care Companion to the Journal of Clinical Psychiatry
Volume20
Issue number2
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Bipolar Disorder
Exanthema
Therapeutics
Movement Disorders
lamotrigine
Hospital Psychiatric Department
Stevens-Johnson Syndrome
Tremor
Liver Diseases
Outpatients
Recurrence

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health

Cite this

Lamotrigine rechallenge in treatment-resistant bipolar disorder. / Inaba, Takayoshi; Sogawa, Rintaro; Mizoguchi, Yoshito; Tateishi, Hiroshi; Kunitake, Yutaka; Kato, Takahiro A.; Monji, Akira.

In: Primary Care Companion to the Journal of Clinical Psychiatry, Vol. 20, No. 2, 17m02231, 01.01.2018.

Research output: Contribution to journalReview article

Inaba, Takayoshi ; Sogawa, Rintaro ; Mizoguchi, Yoshito ; Tateishi, Hiroshi ; Kunitake, Yutaka ; Kato, Takahiro A. ; Monji, Akira. / Lamotrigine rechallenge in treatment-resistant bipolar disorder. In: Primary Care Companion to the Journal of Clinical Psychiatry. 2018 ; Vol. 20, No. 2.
@article{23be78f994e94d91bf5dd8484f82665d,
title = "Lamotrigine rechallenge in treatment-resistant bipolar disorder",
abstract = "Background: Although lamotrigine may be useful for treating patients with treatment-resistant bipolar disorder, some lamotrigine-associated adverse effects, including mild to moderate skin rash, may prevent the continuation of treatment. Methods: We investigated lamotrigine rechallenge for the treatment of bipolar disorder. The present study was based on retrospective chart review of outpatients with bipolar disorder (DSM-5 criteria) who visited the hospital’s psychiatric department between July 2011 and August 2017. The review revealed 12 patients with bipolar disorder who underwent lamotrigine rechallenge following lamotrigine discontinuation due to various adverse reactions, including skin rash. None of the patients showed Stevens-Johnson syndrome. All patients suffered from treatment-resistant bipolar disorder that was refractory to treatments other than lamotrigine. For each patient, the severity of the adverse reaction to lamotrigine was weighed against the potential for therapeutic benefit. Results: In 9 of 12 cases, a positive outcome of lamotrigine rechallenge was observed. In all cases with initial skin rash with very slow titration of lamotrigine, rechallenge was successful with no recurrence of the rash. In the 3 cases for which lamotrigine was unsuccessful, lamotrigine was discontinued owing to movement disorders, ie, oral dyskinesia and action tremor, and liver dysfunction, respectively. Conclusions: The present results suggest that lamotrigine rechallenge may be a viable option for treatment-resistant bipolar disorder.",
author = "Takayoshi Inaba and Rintaro Sogawa and Yoshito Mizoguchi and Hiroshi Tateishi and Yutaka Kunitake and Kato, {Takahiro A.} and Akira Monji",
year = "2018",
month = "1",
day = "1",
doi = "10.4088/PCC.17m02231",
language = "English",
volume = "20",
journal = "The primary care companion for CNS disorders",
issn = "1523-5998",
publisher = "Physicians Postgraduate Press Inc.",
number = "2",

}

TY - JOUR

T1 - Lamotrigine rechallenge in treatment-resistant bipolar disorder

AU - Inaba, Takayoshi

AU - Sogawa, Rintaro

AU - Mizoguchi, Yoshito

AU - Tateishi, Hiroshi

AU - Kunitake, Yutaka

AU - Kato, Takahiro A.

AU - Monji, Akira

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Although lamotrigine may be useful for treating patients with treatment-resistant bipolar disorder, some lamotrigine-associated adverse effects, including mild to moderate skin rash, may prevent the continuation of treatment. Methods: We investigated lamotrigine rechallenge for the treatment of bipolar disorder. The present study was based on retrospective chart review of outpatients with bipolar disorder (DSM-5 criteria) who visited the hospital’s psychiatric department between July 2011 and August 2017. The review revealed 12 patients with bipolar disorder who underwent lamotrigine rechallenge following lamotrigine discontinuation due to various adverse reactions, including skin rash. None of the patients showed Stevens-Johnson syndrome. All patients suffered from treatment-resistant bipolar disorder that was refractory to treatments other than lamotrigine. For each patient, the severity of the adverse reaction to lamotrigine was weighed against the potential for therapeutic benefit. Results: In 9 of 12 cases, a positive outcome of lamotrigine rechallenge was observed. In all cases with initial skin rash with very slow titration of lamotrigine, rechallenge was successful with no recurrence of the rash. In the 3 cases for which lamotrigine was unsuccessful, lamotrigine was discontinued owing to movement disorders, ie, oral dyskinesia and action tremor, and liver dysfunction, respectively. Conclusions: The present results suggest that lamotrigine rechallenge may be a viable option for treatment-resistant bipolar disorder.

AB - Background: Although lamotrigine may be useful for treating patients with treatment-resistant bipolar disorder, some lamotrigine-associated adverse effects, including mild to moderate skin rash, may prevent the continuation of treatment. Methods: We investigated lamotrigine rechallenge for the treatment of bipolar disorder. The present study was based on retrospective chart review of outpatients with bipolar disorder (DSM-5 criteria) who visited the hospital’s psychiatric department between July 2011 and August 2017. The review revealed 12 patients with bipolar disorder who underwent lamotrigine rechallenge following lamotrigine discontinuation due to various adverse reactions, including skin rash. None of the patients showed Stevens-Johnson syndrome. All patients suffered from treatment-resistant bipolar disorder that was refractory to treatments other than lamotrigine. For each patient, the severity of the adverse reaction to lamotrigine was weighed against the potential for therapeutic benefit. Results: In 9 of 12 cases, a positive outcome of lamotrigine rechallenge was observed. In all cases with initial skin rash with very slow titration of lamotrigine, rechallenge was successful with no recurrence of the rash. In the 3 cases for which lamotrigine was unsuccessful, lamotrigine was discontinued owing to movement disorders, ie, oral dyskinesia and action tremor, and liver dysfunction, respectively. Conclusions: The present results suggest that lamotrigine rechallenge may be a viable option for treatment-resistant bipolar disorder.

UR - http://www.scopus.com/inward/record.url?scp=85049696162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049696162&partnerID=8YFLogxK

U2 - 10.4088/PCC.17m02231

DO - 10.4088/PCC.17m02231

M3 - Review article

C2 - 29659202

AN - SCOPUS:85049696162

VL - 20

JO - The primary care companion for CNS disorders

JF - The primary care companion for CNS disorders

SN - 1523-5998

IS - 2

M1 - 17m02231

ER -